Minirin

Polyuria, Nocturia, Polydipsia + 14 more

Treatment

18 Active Studies for Minirin

What is Minirin

Desmopressin

The Generic name of this drug

Treatment Summary

Desmopressin is a synthetic hormone used to control the amount of water in the body. It is typically used to treat conditions such as nocturnal enuresis (bed-wetting) and diabetes insipidus. It can also be used to treat mild cases of hemophilia and von Willebrand's disease. Desmopressin is available in various forms, including intranasal solution, intravenous solution, oral tablet, and oral lyophilisate. Nocdurna, a form of desmopressin acetate, was approved by the FDA in 2018 to treat nocturia

Ddavp

is the brand name

image of different drug pills on a surface

Minirin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ddavp

Desmopressin

1978

101

Effectiveness

How Minirin Affects Patients

Desmopressin is a drug that imitates the natural antidiuretic hormone (ADH) in the body. It works by stimulating receptors in the kidneys to absorb more water and produce less urine. Desmopressin is especially effective in increasing the activity of a protein called factor VIII, which is deficient in people with hemophilia and von Willebrand's disease Type I. Desmopressin does not have the same effect on blood pressure as ADH does. When taken as a nasal spray, desmopressin is less effective than when taken as an injection.

How Minirin works in the body

When desmopressin binds to special receptors in the cells of the distal tubules and collecting ducts of the nephron, it triggers a series of reactions in the cell. This causes more water channels (aquaporins) to be inserted into the membrane of the cell, which makes it more permeable to water.

When to interrupt dosage

The dosage of Minirin is contingent upon the diagnosed ailment, including Minor Surgical Procedures, Pituitary Gland and Surgery, Hemophilia A. The amount is dependent on the technique of delivery as stated in the table hereunder.

Condition

Dosage

Administration

Nocturia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polydipsia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Pituitary Diseases

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Uremia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Diabetes Insipidus, Neurogenic

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Pituitary Surgery

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Nocturnal Enuresis

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Minor Surgical Procedures

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Injection, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered - Nasal, Aerosol, metered, Tablet - Sublingual, Spray, Injection, solution, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Warnings

Minirin has three contraindications. It should not be taken when experiencing any of the conditions presented in the following table.

Minirin Contraindications

Condition

Risk Level

Notes

Hyponatremia

Do Not Combine

Renal Insufficiency

Do Not Combine

Hyponatremia

Do Not Combine

There are 20 known major drug interactions with Minirin.

Common Minirin Drug Interactions

Drug Name

Risk Level

Description

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.

2,5-Dimethoxy-4-ethylthioamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-Methoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.

Minirin Toxicity & Overdose Risk

Taking too much desmopressin can lead to low sodium levels in the blood (hyponatremia). Symptoms of hyponatremia can include seizures, confusion, drowsiness, headaches, irregular heartbeat, and swelling. If you have taken too much desmopressin, you should reduce the dose or stop using it altogether. You should also get your sodium levels checked and seek medical treatment.

Minirin Novel Uses: Which Conditions Have a Clinical Trial Featuring Minirin?

30 active investigations are examining the potential of Minirin to ameliorate Polyuria, Hemophilia A and Hemophilia B.

Condition

Clinical Trials

Trial Phases

Pituitary Diseases

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Pituitary Surgery

0 Actively Recruiting

von Willebrand Disease

5 Actively Recruiting

Phase 3, Phase 1, Phase 2

Hemophilia A

3 Actively Recruiting

Phase 3, Phase 1

Uremia

0 Actively Recruiting

Nocturia

4 Actively Recruiting

Not Applicable, Phase 4

Polyuria

0 Actively Recruiting

Minor Surgical Procedures

0 Actively Recruiting

von Willebrand Disease

0 Actively Recruiting

Polydipsia

0 Actively Recruiting

Diabetes Insipidus, Neurogenic

2 Actively Recruiting

Phase 1, Early Phase 1

Hemophilia A

0 Actively Recruiting

Polyuria

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Hemophilia A

0 Actively Recruiting

Nocturnal Enuresis

4 Actively Recruiting

Phase 3, Not Applicable

Minirin Reviews: What are patients saying about Minirin?

3.3

Patient Review

10/20/2015

Minirin for Bedwetting

This medication wasn't effective every day, but it did work some days.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about minirin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Minirin used for?

"Minirin tablets are indicated to treat cranial diabetes insipidus and primary nocturnal enuresis (bedwetting) in patients from 6 years of age who are refractory to an alarm system or for whom an alarm system is not appropriate."

Answered by AI

Is Minirin over the counter?

"This medicine only requires a prescription from your doctor if you have low levels of specific agents that result in less bleeding."

Answered by AI

How do you give a Minirin?

"Place the Minirin Melt under your tongue. It will dissolve without needing any water. Please read the instruction leaflet that comes with the Minirin Melt."

Answered by AI

How long can you take Minirin for?

"The recommended amount of time to take Minirin Tablets for bedwetting is 3 months. After this period, it is recommended that you take a week break from the medication to see if the bedwetting has stopped. If it has not stopped, continue taking the medication for another 3 months. Your doctor will advise you on the best course of action."

Answered by AI

Clinical Trials for Minirin

Have you considered Minirin clinical trials?

We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.
Go to Trials
Image of Children's Hospital Los Angeles in Los Angeles, United States.

Timed Awakening for Bedwetting

6 - 17
All Sexes
Los Angeles, CA

The goal of this clinical trial is to evaluate the effectiveness of nightly timed awakening in the treatment of nocturnal enuresis in children aged 6-17. The main questions it aims to: * Determine feasibility of nightly timed awakenings * Determine the role, if any, of comorbidities on resolution of enuresis * Determine incidence of daytime accidents * Obtain patient and parental satisfaction scores Researchers will compare a control group to treatment groups to see if there is any impact on nocturnal enuresis. Participants will be woken up by parents in the middle of the night to use the restroom. In addition, participants will receive 30 minute psychotherapy sessions using telehealth.

Waitlist Available
Has No Placebo

Children's Hospital Los Angeles

Evalynn Vasquez, MD

Image of Massachusetts General Hospital in Boston, United States.

Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

18 - 65
All Sexes
Boston, MA

This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that: 1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control. 2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.

Phase < 1
Recruiting

Massachusetts General Hospital

Elizabeth A Lawson, MD

Image of Albany Medical College in Albany, United States.

TENS for Bedwetting

5 - 17
All Sexes
Albany, NY

Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into two groups of 35 patients each.Group 1 will be the high pulse width set at 260us. Group 2 will be the low pulse width set at 50us. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a pulse width determined by randomization, frequency of 10Hz, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 30 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Bowel \& Bladder Questionnaire (BBQ), a validated tool for measuring symptoms in children with voiding dysfunction \[6\]; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.

Recruiting
Has No Placebo

Albany Medical College

Adam Howe, MD

Have you considered Minirin clinical trials?

We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.
Go to Trials

Have you considered Minirin clinical trials?

We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.
Go to Trials